Another stem cell trial

Discuss stem cells, adult and embryonic, and their therapeutic potential for MS here.
Post Reply
User avatar
Family Elder
Posts: 1608
Joined: Wed Aug 11, 2004 2:00 pm

Another stem cell trial

Post by dignan » Sun Nov 18, 2007 1:54 pm

This stem cell trial is a new one to me.

Donor Stem Cell Transplantation for the Treatment of Multiple Sclerosis

This study is currently recruiting participants.
Verified by University of Louisville, July 2007
Phase I / II

While the cause of MS in not known, there is an autoimmune component that destroys nerve cells. Autoimmunity is a condition where an individual's immune system attacks his/her own cells. Bone marrow stem cell transplantation has been shown to halt autoimmunity. Stem cell transplant can be performed using the patient’s own cells, or donor cells. The general consensus in the field is that donor transplant is most likely to halt disease progression. This study is designed to evaluate the safety of a donor transplant procedure as a therapy for relapsing remitting multiple sclerosis (RRMS).

Two factors limit the widespread application of traditional donor stem cell transplant: 1) preparing the patient for transplant (conditioning); and 2) graft-versus-host disease (GVHD). Traditional conditioning destroys the recipient's immune system and requires that the marrow transplant be successful because the patient is unable to fight off infection if the donor cells do not survive. GVHD occurs when donor immune cells recognize the recipient’s cells as foreign tissue and attack them. Severe GVHD can result in death. This study utilizes a new approach to conditioning which leaves the patient's immune system intact. The transplant product is depleted of GVHD-producing cells but retains tolerance-promoting cells, called facilitating cells, which are intended to ensure the donor and recipient cells coexists peacefully. The toxicity of conditioning and transplantation is significantly reduced. The end result is a marrow system that contains recipient and donor cells, a state called mixed chimerism.

In this study, we will determine the appropriate cell dose to safely establish mixed chimerism following partial conditioning in patients with RRMS. The study takes a gradual approach to increasing the cell dose to achieve mixed chimerism. Each patient will receive a cell dose one unit above the dose received by the most recent safely transplanted patient. We believe this study will provide a breakthrough in the treatment of MS. The goal of this proposal is to evaluate the potential of safely establishing mixed chimerism to interrupt the autoimmune process and end the devastating effects of MS. link

Post Reply
  • Similar Topics
    Last post
  • Domestic Stem cell therapy
    by HUD45 » Fri May 04, 2018 8:33 am » in Stem Cells
    16 Replies
    Last post by HUD45
    Fri Jul 20, 2018 6:21 am
  • Simvastatin Trial & ponderings
    by Jaded » Tue Feb 26, 2019 9:07 am » in General Discussion
    1 Replies
    Last post by Jaded
    Tue Feb 26, 2019 12:31 pm
  • Young Plasma Clinical Trial for MS
    by SAW » Mon Sep 24, 2018 4:32 pm » in General Discussion
    2 Replies
    Last post by ElliotB
    Sat Sep 29, 2018 3:08 am
  • Simvastatin trial for SPMS in UK recruiting
    by frodo » Fri Mar 15, 2019 4:42 am » in General Discussion
    1 Replies
    Last post by Jaded
    Wed Mar 20, 2019 9:36 am
  • Lipoic acid inhibits B cell migration across BBB in RRMS
    by NHE » Sun Sep 02, 2018 12:03 am » in Natural Approach
    1 Replies
    Last post by Petr75
    Mon Sep 03, 2018 8:09 am